IGKV2D-24 and schizophrenia: For instance, drugs with different pharmacological mechanisms, such as α7-nicotinic agonists and 5-HT6 receptor antagonists produced much smaller improvements in cognition in schizophrenia clinical trials than would have been predicted from preclinical data, even in studies using disease models rather than normal animals.